ClinicalTrials.gg
CompletedNCT05078944Updated May 22, 2026Results posted

Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture

An interventional study of Active acupuncture and Sham acupuncture in Alzheimer Disease 1, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Completed at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Enrollment
67th of 176
160 · median 100
Started
2022
with 22 others
No phase
78 of 260
47 open now
Registered
80th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 67th largest by enrollment of the 176 interventional ones that give a count, is one of 23 that started in 2022, is one of 78 with no phase, and was the 80th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

To determine if adjunctive acupuncture acts as an AD treatment rather than a placebo.

Read the detailed description

Acupuncture is used as an adjuvant therapy for Alzheimer's disease (AD), but available evidence for efficacy is weak. The aim is to determine if adjunctive acupuncture acts as an AD treatment rather than a placebo.

This is a randomized, participant-masked, sham-controlled trial. One hundred and sixty participants with mild AD will be randomly assigned (1:1) to either active acupuncture or non-penetrating sham acupuncture (3 times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks). The primary efficacy outcome is the change from baseline in the Alzheimer's disease Assessment Scale (ADAS-cog12). Secondary efficacy outcomes include other assessments of the Mini-Mental State Examination (MMSE), the Alzheimer's disease Cooperative Study-Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI).

03

Conditions studied

  • Alzheimer Disease 1

Browse trials for

Keywords

  • Alzheimer's Disease
  • Electroacupuncture
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets the diagnostic criteria for probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)
  • Scored 1.0 by the Clinical Dementia Rating Scale (CDR) Global Score

Exclusion criteria

Exclusion Criteria:

  • Dementia due to other causes
  • Evidence of a or unstable psychiatric disorder
  • Has irritable bowel syndrome or inflammatory bowel disease
  • Has unstable or severe cardiovascular, hepatic, renal, respiratory, endocrinologic, neurologic diseases and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study
  • Has visual or hearing disorder, defeating completion of evaluation
  • Use of AD therapy (except for donepezil hydrochloride) which cannot be stopped
  • Use of antibiotics within 1 month prior to enrollment
  • Has a history of gastrointestinal surgery (except for appendicitis and hernia surgery)
  • Without a reliable caregiver who will accompany the participant during treatment and assessment, and monitor administration of the prescribed medications
  • With cardiac pacemaker or metal allergy
  • Once experienced electroacupuncture treatment before at any time (manual acupuncture is allowed)
  • Premenopausal woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Active acupuncture + Donepezil

    Active acupuncture treatment is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Acupuncture + Drug: Donepezil hydrochloride

    Device: Active acupuncture · Drug: Donepezil Hydrochloride

  • Sham comparator
    Sham acupuncture + Donepezil

    Sham acupuncture treatment with no skin penetration and no current output on sham acupoints is to be taken 3 sessions weekly over a period of 14 weeks. Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily over 32 weeks (including 4-week run-in) Intervention: Device: Sham acupuncture + Drug: Donepezil hydrochloride

    Device: Sham acupuncture · Drug: Donepezil Hydrochloride

Interventions

  • DeviceActive acupuncture

    Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.

  • DeviceSham acupuncture

    Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56). After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min.

  • DrugDonepezilStudies of DonepezilDonepezil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 12 Item Subscore (ADAS-Cog12)

    The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS consists of 12 items (ranges from 0 to 75). Higher scores indicating greater cognitive impairment.

    Time frame: Week 14

Secondary outcomes

  1. Change From Baseline in Mini-Mental State Examination (MMSE)

    MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity.

    Time frame: Baseline, Week 7, Week 14, Week 21, Week 28

  2. Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)

    The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity.

    Time frame: Baseline, Week 7, Week 14, Week 21, Week 28

  3. Change From Baseline in Neuropsychiatric Inventory (NPI)

    NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 0 to 144, with lower scores indicating fewer behavioral disturbances

    Time frame: Baseline, Week 7, Week 14, Week 21, Week 28

  4. Treatment Credibility

    The treatment credibility scale will be assessed by asking participants to rate their response to four questions on a 5-point scale developed by Borkovec and Nau. Total score ranges from 0 to 20; higher score indicates greater treatment credibility.

    Time frame: Week 1, Week 14

  5. Incidence of Adverse Events

    Including subcutaneous hematoma, local errhysis at acupoints, sharp pain, palpitation, nausea, dizziness and faint during acupuncture.

    Time frame: Week -4 to Week 28

  6. Change in Gut Microbiota Diversity Based on 16S rRNA Gene Sequencing Analysis

    Stool samples will be processed to extract DNA, followed by 16S rRNA gene sequencing analysis using QIIME and R packages (v3.2.0).

    Time frame: Baseline, Week 14, Week 28

07

Results

Posted May 22, 2026

Participant flow

Of 192 patients screened, 160 were randomized between June 30, 2022, and January 20, 2025.

Participant flow — Overall Study
MilestoneActive Acupuncture + DonepezilSham Acupuncture + Donepezil
Started8080
Completed6264
Not completed1816

Outcome measures

PrimaryChange From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 12 Item Subscore (ADAS-Cog12)

The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS consists of 12 items (ranges from 0 to 75). Higher scores indicating greater cognitive impairment.

Time frame:
Week 14
Reported as:
Mean · point
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 12 Item Subscore (ADAS-Cog12)
pointActive Acupuncture + DonepezilSham Acupuncture + Donepezil
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 12 Item Subscore (ADAS-Cog12)-1.20 ± 0.310.36 ± 0.32
SecondaryChange From Baseline in Mini-Mental State Examination (MMSE)

MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity.

Time frame:
Baseline, Week 7, Week 14, Week 21, Week 28

Results for this outcome have not been posted.

SecondaryChange From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)

The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity.

Time frame:
Baseline, Week 7, Week 14, Week 21, Week 28

Results for this outcome have not been posted.

SecondaryChange From Baseline in Neuropsychiatric Inventory (NPI)

NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 0 to 144, with lower scores indicating fewer behavioral disturbances

Time frame:
Baseline, Week 7, Week 14, Week 21, Week 28

Results for this outcome have not been posted.

SecondaryTreatment Credibility

The treatment credibility scale will be assessed by asking participants to rate their response to four questions on a 5-point scale developed by Borkovec and Nau. Total score ranges from 0 to 20; higher score indicates greater treatment credibility.

Time frame:
Week 1, Week 14

Results for this outcome have not been posted.

SecondaryIncidence of Adverse Events

Including subcutaneous hematoma, local errhysis at acupoints, sharp pain, palpitation, nausea, dizziness and faint during acupuncture.

Time frame:
Week -4 to Week 28

Results for this outcome have not been posted.

SecondaryChange in Gut Microbiota Diversity Based on 16S rRNA Gene Sequencing Analysis

Stool samples will be processed to extract DNA, followed by 16S rRNA gene sequencing analysis using QIIME and R packages (v3.2.0).

Time frame:
Baseline, Week 14, Week 28

Results for this outcome have not been posted.

Adverse events

Collected over from enrollment until end of follow-up, up to 28 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Acupuncture + Donepezil0/78 (0%)0/78 (0%)29/78 (37.2%)
Sham Acupuncture + Donepezil0/79 (0%)1/79 (1.3%)35/79 (44.3%)
Most frequent serious events
Most frequent serious events
EventActive Acupuncture + DonepezilSham Acupuncture + Donepezil
Cerebrovascular accidentVascular disorders0/781/79
Most frequent other events
Most frequent other events
EventActive Acupuncture + DonepezilSham Acupuncture + Donepezil
COVID-19Infections and infestations11/7814/79
DiarrheaGastrointestinal disorders2/785/79
Subcutaneous hematomaSkin and subcutaneous tissue disorders4/780/79
Urinary tract infectionRenal and urinary disorders3/784/79
HeadacheGeneral disorders2/784/79
FallInjury, poisoning and procedural complications3/783/79
NauseaGastrointestinal disorders1/783/79
FatigueGeneral disorders2/781/79
DizzinessGeneral disorders0/782/79
Heart palpitationsCardiac disorders1/780/79

Baseline characteristics

Modified intention-to-treat analysis was adopted. Two in the Acive acupuncture + Donepezil group and 1 in the Sham acupuncture + Donepezil gruop were excluded from analysis due to lack of 1 valid postbasline assessment.

Age, Continuous
Age, Continuous(year)Active Acupuncture + DonepezilSham Acupuncture + DonepezilTotal
Mean69.2 ± 7.466 ± 867.6 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Active Acupuncture + DonepezilSham Acupuncture + DonepezilTotal
Female484391
Male303666
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Active Acupuncture + DonepezilSham Acupuncture + DonepezilTotal
Count of participants——0
Acetylcholinesterase inhibitor or memantine use history
Acetylcholinesterase inhibitor or memantine use history(Participants)Active Acupuncture + DonepezilSham Acupuncture + DonepezilTotal
Count of participants6568133
08

Study locations

1 site
  • Shanghai Institute of Acupuncture, Moxibustion and Meridian Organization
    Shanghai, 200030, China
09

References and documents

Publications

  • Kong X, Han R, Fan X, Wei K, Ma Z, Yang G, Zhao Y, Yang Y, Yang Y, Hong J, Liu J, Zhang D, Ma X. Acupuncture as an adjunct therapy for mild Alzheimer's disease: A randomized clinical trial. J Alzheimers Dis. 2026 May;111(2):757-767. doi: 10.1177/13872877261435880. Epub 2026 Mar 30. PubMed 41910461 ↗
  • Kong X, Ma Z, Tang R, Wang X, Wei K, Yang G, Yang Y, Zhao Y, Zhang D, Xie C, Wang G, Ma X. Efficacy of acupuncture in patients with mild Alzheimer's disease and its impact on gut microbiota: Study protocol for a randomized sham-controlled trial. Front Med (Lausanne). 2023 Feb 23;10:1014113. doi: 10.3389/fmed.2023.1014113. eCollection 2023. PubMed 36910501 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2025, 38 months.

Results were first posted in May 2026, 8 months after primary completion.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 38 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Oct 15, 2021
StartActual
Jun 30, 2022
Primary completionActual
Sep 10, 2025
CompletionActual
Sep 10, 2025
Results first posted
May 22, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05078944
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Responsible party
Sponsor
First posted
Oct 15, 2021
Start date
Jun 30, 2022
Primary completion
Sep 10, 2025
Completion
Sep 10, 2025
Results posted
May 22, 2026
Last update
May 22, 2026

Study contacts

Xiaopeng Ma, MD, PhD
study chair · Shanghai Institute of Acupuncture, Moxibustion and Meridian

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion